Formulation research forms the most significant pillar of RPG’s growth strategy. Formulation R&D is proficient in delivering innovative, critical, patentable, branded as well as generic formulations with expertise and capabilities to develop all types of dosage forms including niche products using highly specialised technology products including that of moisture sensitive drugs for the domestic and global market.
“The extensive research work has led to breakthrough inventions, which have been protected under patent applications.”
RPG develops and applies skills to ensure the quality of its products right from the design to the manufacturing stage for patient’s safety and efficacy of the products.
The development process for the products followed, ensures formulation development based on Quality by Design (QBD) principles enabling robust, reproducible and regulatory complied products in the market. The R & D Centre has the formulation development pipeline of complex products where major development is for international markets specifically in Immunosuppressant, CNS, CVS etc. therapies.
The API/Bulk Drug Research Facility, approved by Department of Scientific and Industrial Research (DSIR), Government of India, is located in Navi Mumbai. Manned by a pool of skilled scientists, the R&D efforts are directed towards development of non-infringing process technology of Fully Synthetic API and Semi Synthetic API.
Non-infringing synthetic process technology developed for Risperidon API.
Innovative process technology for Pantoprazole sodium sesquihydrate synthesis.
Proprietary process for Clopidogrel Bisulphate Form 1 API production.
Advanced process development for Tolvaptan API synthesis.
Specialized synthetic route for Clopidogrel Free Base API.